Skip to content

menu

Reed Smith LLP logo
HomeAboutSubscribeTopicsOur ServicesContact
Search
Close

Health Industry Washington Watch

Updates by Reed Smith on U.S. legislative & regulatory developments affecting the health care industry

FDA Seeks Comments on Drug Company Social Media Guidance

By Debra A. McCurdy on 20 January 2014
Print:
Email this postTweet this postLike this postShare this post on LinkedIn

As reported on our Life Sciences Legal Update blog, the FDA has issued draft guidance addressing the unique challenges of drug promotion in the age of social media. Specifically, the draft guidance addresses how to submit interactive promotional media for postmarket review.  Comments on the document, “Draft Guidance for Industry on Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics,” are due April 14, 2014.

Posted in Department of Health & Human Services Regulations, Food & Drug Administration Regulations, Other FDA Developments
Tags: Department of Health & Human Services, Drug Advertising, Drugs, FDA, Food & Drug Administration Developments, Other FDA Developments, social media
Related Posts
FDA codifies requirements for the medical device De Novo classification process
October 14, 2021
FDA clarifies evidence and knowledge requirements in intended use final rule
August 26, 2021
Marketers Beware: As COVID-19 cases increase, FDA, FTC increase efforts to crack down on fraudulent and deceptive marketing and sales of purported ‘Virus Cures’
December 1, 2020

Subscribe to Health Industry Washington Watch

Updates direct to your inbox
Subscribe by Email

Links & Resources

Key Regulatory Sites

  • CMS
  • FDA
  • Federal Register
  • HHS
  • HHS OIG

Key Legislative Sites

  • Congressional Record
  • House Energy and Commerce Committee
  • House Ways and Means Committee
  • Senate Finance Committee
  • Thomas (Library of Congress)

Health Industry Washington Watch

View Our Network of Blogs
Published by
Reed Smith LLP logo
RSS Twitter Facebook LinkedIn youtube
Privacy PolicyDisclaimer

About Our Firm

Reed Smith represents many of the world’s leading companies in complex litigation and other high-stakes disputes, cross-border and other strategic transactions, and crucial regulatory matters.

Read More...

Topics

Archives

Copyright © 2023, Reed Smith LLP. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo